Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1850 in Pediatric Hypophosphatasia
NCT06079359Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- May 2024
- Primary completion
- Jan 2026
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 16
01
Overview
A Phase 3 trial of efzimfotase alfa in hypophosphatasia (HPP), sponsored by Alexion Pharmaceuticals. Started May 2024; status: active, not recruiting.
02
Drugs
efzimfotase alfa
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on NCT06079359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06079359.